1. MANAGING MARKET DISRUPTIONS
Preparing for threats and opportunities impacting products, platforms or markets
The impact of 'market disruptors'
can be felt along the whole
product lifecycle, from early
stage R&D and innovation
BIOSIMILARS through to mature product LCM
MARKET ENTRY
strategies. Datamonitor Consulting
MARKET INSIGHT
STRATEGY DEVELOPMENT analyzes market disruptors to
help you understand the impact,
your options, and potential for
commercial gain. This is developed
into an action plan to mitigate risk
and/or maximize opportunity.
MANAGING DISRUPTIONS
PERSONALIZED HEALTHCARE
To ensure that you are ahead of
COMPETITOR ANALYSIS the game, our surveillance trackers
Maximizing opportunities and PRODUCT LAUNCH SUPPORT and defence/opportunity plans help
mitigating risks created by new AND GUIDANCE
you prepare for developments in
market dynamics the marketplace. We inform your
decision making to help you to
commercially position your brand
and product portfolio in alignment
with market trends. We support
your thorough understanding of all
FUTURE DISRUPTORS facts, possibilities and options; we
MARKET MONITORING
go beyond information sourcing
INTERPRETING AND PRIORITIZING
to interpret the likely threats and
opportunities you're facing.
BIOSIMILARS PERSONALIZED HEALTHCARE
Datamonitor Consulting’s Biosimilars Practice provides deep insight Datamonitor Consulting provides detailed assessments of the
into the biosimilars landscape. We support you in understanding opportunities and threats that personalized healthcare provides,
and quantifying the potential challenges and opportunities within the considering key stakeholders including payers, regulators and
market. Aligned with many of Datamonitor Consulting’s other areas physicians.
of expertise, our consultants are able to advise on biologics LCM
strategy, provide insights into biosimilar opportunity assessments Through in-depth insight and analysis we look at how the market
(including forecasting, licensing and partnership opportunities) and is changing and how it will impact your product/portfolio. Our
support you in keeping up to date with the ever-changing biosimilars consultants inform your decision making processes through a
landscape. combination of total market analysis and assessment of implications
for your brand. This incorporates a gap analysis and assessment of
market forces and their implications.
Our consultants operate globally; our head offices are located in:
UK 119 Farringdon Road, London EC1R 3DA | +44 (0)20 7675 7000
US 52 Vanderbilt Avenue, 7th Floor, New York, NY 10017 | +1 (212) 686 7400 info@datamonitorconsulting.com
Japan 7th Kotakudo GINZA Building, 5-14-5, Ginza, Chuo, Tokyo 104-0061 | +81 (0)3 5148 7910 www.datamonitorconsulting.com

2. RESULTS IN PRACTICE: HOW WE’VE HELPED OTHERS
OUR EXPERTISE
Our specialists’ deep-level expertise in biosimilars and personalized healthcare is gained from past positions within biopharmaceutical, biotech,
clinical research and management consulting organizations. We provide consultants with expertise in:
• Finding, understanding and quantifying risks and opportunities
• Supporting the development of actionable lifecycle management (LCM) strategies for biologic assets
• Thought leadership with expert understanding of market dynamics
• Interpreting what market changes mean to you and how key events can impact your business moving forward
We go beyond simple “data collection” and reporting, combining market insight with leading-edge workshop facilitation expertise to drive robust
decision making at all levels of your business.
BIOSIMILAR THREATS AND OPPORTUNITIES PERSONALIZED HEALTHCARE
The Issue The Issue
Reflecting both sides of the challenge, our A large pharma client sought to understand
clients have required guidance to monitor and how the introduction of personalized healthcare
mitigate the threats to their biologics businesses, (PHC) affects the commercial performance of
whilst also needing rapid decision making drugs launching into, or already on the market.
support to evaluate their potential entry into the
biosimilars market.
Our Approach Our Approach
Following secondary and primary research, our Through in-depth secondary market research,
consultants managed a cross-functional client detailed quantitative case study analysis,
team at a major biotech to prioritize the most and primary interviews with internal and
effective elements of its biosimilar defence external experts, we were able to identify
strategy. the key market factors determining whether
PHC has a positive or negative impact upon a
For a Japanese client considering investment in pharmaceutical product.
the biosimilars markets, we conducted rigorous
secondary research and intensive evaluations
across multiple workstreams to deliver robust
understanding of local market drivers.
The Result The Result
Our biotech client benefited from a multi- A PHC checklist of actions was developed along
scenario impact model and decision support with an exhaustive report including ‘actions to
matrix that enabled them to plan for the impact imitate and to avoid’. The client used our report
of biosimilars on their business in nine individual and quantitative model to inform their broader
markets. In Japan, our client adjusted their organization about the impact of PHC on drug
biosimilars entry strategy, based on our timely sales across classes or disease areas.
coverage and synthesis of local market insights.
Our consultants operate globally; our head offices are located in:
UK 119 Farringdon Road, London EC1R 3DA | +44 (0)20 7675 7000
US 52 Vanderbilt Avenue, 7th Floor, New York, NY 10017 | +1 (212) 686 7400 info@datamonitorconsulting.com
Japan 7th Kotakudo GINZA Building, 5-14-5, Ginza, Chuo, Tokyo 104-0061 | +81 (0)3 5148 7910 www.datamonitorconsulting.com